

## **Forbius to Present at the 18<sup>th</sup> Annual Needham Healthcare Conference**

Austin, TX, and Montreal, QC (Apr. 08, 2019) – Forbius, a clinical-stage company that develops novel biologics for the treatment of cancer and fibrosis, announced today that Ilia Tikhomirov, CEO of Forbius, will be presenting at the 18<sup>th</sup> Annual Needham Healthcare Conference.

Mr. Tikhomirov's presentation will take place Tuesday, April 9th at 1:30 PM EST in Track 1, 3<sup>rd</sup> floor at the Westin Grand Central Hotel in New York.

### **About Forbius: Targeting TGF-beta and EGFR Pathways in Fibrosis and Cancer**

Forbius is a clinical-stage protein engineering company that designs and develops novel biologics for the treatment of fibrosis and cancer. Our current focus is the development of agents targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways.

Our lead program targeting the TGF-beta pathway is AVID200. AVID200 is a rationally designed and highly potent TGF-beta 1 & 3 inhibitor. This TGF-beta isoform selectivity was chosen in order to achieve an optimal therapeutic index. AVID200 is currently being evaluated in two Phase 1b clinical trials in fibrotic indications, as well as a Phase 1 clinical trial in solid tumors. Additional clinical trials in fibrotic indications are planned for 2019.

Forbius' lead program targeting the EGFR pathway is AVID100. AVID100 is an anti-EGFR antibody-drug conjugate. This program has completed a Phase 1 clinical trial and has commenced Phase 2a clinical trials in EGFR-overexpressing solid tumors.

For more information, please visit [www.forbius.com](http://www.forbius.com).